Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - Journal of Thoracic Oncology
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - ScienceDirect
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - ScienceDirect
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
PACIFIC Trial: Adjuvant Immunotherapy Improves Overall Survival (OS) in Stage III NSCLC – BTOG | British Thoracic Oncology Group
PACIFIC Trial Leads to Durvalumab Approval in United States - ILCN.org (ILCN/WCLC)
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
IMFINZI® (durvalumab) Efficacy for Unresectable Stage III NSCLC
Frontiers | A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer | Oncology
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial - Journal of Thoracic Oncology
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
IMFINZI® (durvalumab) Efficacy for Unresectable Stage III NSCLC
First-line Durvalumab Improves Survival
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial - The Lancet
Cancers | Free Full-Text | Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer | HTML
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
IMFINZI® (durvalumab) Efficacy for Unresectable Stage III NSCLC
PDF) PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity - memoinOncology
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology
PDF) Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited)
